Bvf Inc Mei Pharma, Inc. Transaction History

Bvf Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$2.6 - $3.65 $145,854 - $204,757	-56,098 Reduced 1.56%	3,532,057 $10.1 Million
Q1 2021 May 17, 2021	SELL	$2.73 - $4.5 $1.26 Million - $2.07 Million	-461,007 Reduced 11.39%	3,588,155 $12.3 Million
Q4 2020 Feb 12, 2021	SELL	$2.6 - $3.32 $80,600 - $102,920	-31,000 Reduced 0.76%	4,049,162 $10.7 Million
Q3 2020 Nov 13, 2020	SELL	$2.46 - $4.27 $123,000 - $213,499	-50,000 Reduced 1.21%	4,080,162 $12.7 Million
Q2 2020 Aug 14, 2020	SELL	$1.45 - $4.3 $1.33 Million - $3.94 Million	-916,110 Reduced 18.15%	4,130,162 $17.1 Million
Q1 2020 May 15, 2020	SELL	$0.75 - $2.55 $225,000 - $765,000	-300,000 Reduced 5.61%	5,046,272 $8.12 Million
Q4 2019 Feb 14, 2020	BUY	$1.65 - $2.48 $5.16 Million - $7.75 Million	3,125,000 Added 140.69%	5,346,272 $13.3 Million
Q2 2019 Aug 14, 2019	SELL	$2.45 - $3.32 $1.17 Million - $1.59 Million	-477,483 Reduced 17.69%	2,221,272 $5.55 Million
Q1 2019 May 15, 2019	SELL	$2.52 - $3.24 $705,481 - $907,047	-279,953 Reduced 9.4%	2,698,755 $8.29 Million
Q4 2018 Feb 14, 2019	SELL	$1.92 - $4.1 $195,072 - $416,559	-101,600 Reduced 3.3%	2,978,708 $7.86 Million
Q2 2018 Aug 14, 2018	BUY	$1.89 - $4.95 $5.82 Million - $15.2 Million	3,080,308 New	3,080,308 $12.1 Million

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $366M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.